Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Hazard Rate01:11

Hazard Rate

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Randomized Experiments01:13

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical analysis of disease onset during lifespan with left truncation.

Biometrics·2026
Same author

Eligibility of men vs. women in Alzheimer's trials: Inclusive vs. representative.

The journal of prevention of Alzheimer's disease·2026
Same author

Interrupted Time Series Methods for Nonrandom Sampling Study Designs With Known Sampling Weights.

Statistics in medicine·2026
Same author

Systematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cells.

Cell·2026
Same author

Validation of a Renal Papillary Grading System: Comparison of Patients Forming Calcium Oxalate and Apatite Stones.

Journal of endourology·2026
Same author

Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer's trials.

The journal of prevention of Alzheimer's disease·2026

Related Experiment Video

Updated: May 20, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Robust inference in discrete hazard models for randomized clinical trials.

Vinh Q Nguyen1, Daniel L Gillen

  • 1Department of Statistics, University of California, Irvine, CA, USA. vqnguyen@uci.edu

Lifetime Data Analysis
|July 20, 2012
PubMed
Summary

Analyzing discrete time-to-event data in clinical trials, this study addresses violations of the constant treatment effect assumption in discrete hazard models. A novel estimator is proposed to provide scientifically meaningful and reproducible statistical inference, removing dependence on censoring mechanisms.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Related Experiment Videos

Last Updated: May 20, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Area of Science:

  • Biostatistics
  • Clinical Trials Methodology
  • Survival Analysis

Background:

  • Discrete time-to-event data are prevalent in clinical trials, particularly in oncology, where events are assessed at scheduled intervals.
  • Standard discrete hazard models and proportional odds models are commonly used for analyzing such data.
  • The assumption of a constant treatment effect is often violated in real-world clinical trial scenarios.

Purpose of the Study:

  • To investigate the estimation of marginal treatment effects in discrete hazard models when the constant treatment effect assumption is not met.
  • To develop a robust statistical method that yields consistent and meaningful inference.
  • To propose an estimator that is independent of the underlying censoring distribution.

Main Methods:

  • Utilized discrete hazard models, including discrete-time proportional hazards and continuation ratio models.
  • Investigated the properties of existing estimators under violated constant treatment effect assumptions.
  • Developed and derived the asymptotic distribution of a novel estimator designed to be robust to censoring mechanisms.

Main Results:

  • Demonstrated that standard discrete hazard model estimators are consistent for a parameter dependent on the censoring distribution.
  • Proposed a new estimator that successfully removes the dependence on the censoring mechanism.
  • The proposed estimator facilitates statistically sound and reproducible inference.

Conclusions:

  • The developed estimator provides a scientifically meaningful approach to analyzing discrete time-to-event data with non-constant treatment effects.
  • This methodology enhances the reliability and reproducibility of statistical inference in clinical trials.
  • Simulation studies confirmed the performance of the proposed estimator in finite samples.